Trans-Hit Bio (THB) is the worldwide biospecimen access CRO, founded in 2009, headquartered in Montréal, Québec, with a most extensive collection capability for biospecimens and clinical samples through an unrivalled worldwide partnered-network of state-of-the-art biorepositories. The company, led by a team of scientists with a solid background in biomedical research, advises and provides Industry with the best solutions to help design and conduct studies in various fields including oncology, infectiology, and central nervous system (CNS) diseases. Continuous support is provided throughout the entire process from initial request to the moment the samples are delivered, and beyond.
Located in Phoenix, Arizona, Maricopa Integrated Health System (MIHS) has a proud tradition of being both the community safety net health care system, with a mission and commitment to serving the underserved and Arizona’s only public teaching hospital. MIHS consists of Maricopa Medical Center, the only Level 1 Trauma Center in Arizona verified by the American College of Surgeons to care for both adults and children, Arizona’s only nationally verified Burn Center serving the entire Southwestern United States, MIHS’ McDowell Healthcare Center, which is the largest provider of HIV primary care in Arizona, the refugee Women’s Health Clinic, the Arizona Children’s Center, two behavioral health centers, and 13 neighborhood Family Health Centers.
Trans-Hit Bio and MIHS have signed an exclusive commercial agreement. Through this agreement, THB will promote MIHS’ capabilities in prospectively procuring high-quality biospecimen collections from their various clinical centers: Emergency, Trauma, Pediatric, Cardiology, Maternity, Women’s Health, and many other departments.
“Working with Trans-Hit Bio has significantly raised the profile of the MIHS Biobank and its capabilities and given us a degree of visibility that we could not have reached on our own, without a great deal of time and effort. We are very happy with the number and quality of studies from Industry Sponsors brought by Trans-Hit Bio, which has increased our contribution to meaningful research. In addition, we appreciate the fact that Trans-Hit Bio adheres to a policy of transparency and traceability of human specimens and is open to facilitating scientific and technical exchanges with the end-users,” said Dr. Lora Nordstrom, Academic Research Program Manager & Biobank Manager at the MIHS.
“This agreement strengthens Trans-Hit Bio’s presence in the USA and is a valuable addition to our worldwide network of academic and hospital-based biobanks for sourcing high-grade biospecimens. We take great pleasure in working with the MIHS team who is very motivated, knowledgeable and professional, as they are also well versed to Good Clinical Practices,” said Dr. Pascal Puchois, Chief Executive Officer at Trans-Hit Bio.
Source:
